E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Hepatitis B |
Epatite B cronica |
|
E.1.1.1 | Medical condition in easily understood language |
Long term infection with the hepatitis B virus |
Infezione a lungo termine con virus dell'epatite B |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10008910 |
E.1.2 | Term | Chronic hepatitis B |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To characterize the long term (i.e., 96 weeks of follow up) bone safety profile of open-label Tenofovir DF treatment in CHB infected adolescents. This includes prospectively evaluating and comparing the bone mineral density (BMD) change between CHB- infected adolescents 12 to < 18 years of age treated with Tenofovir DF in European treatment centers who are assigned to one of two schedules for renal and bone laboratory monitoring and BMD measurement. Primary study outcome will be the percent changes in BMD from Baseline through study Week 96. |
Caratterizzare il profilo di sicurezza osseo a lungo termine (96 settimane di follow up) del trattamento con Tenofovir DF in aperto in adolescenti con CHB. Ci¿ comporta la valutazione e il confronto prospettici della variazione della densit¿ minerale ossea (DMO) tra gli adolescenti di et¿ compresa tra 12 e <18 anni con epatite cronica B (CHB) trattati con Tenofovir DF presso centri di trattamento europei e assegnati a uno di due programmi di monitoraggio con esami di laboratorio per la funzionalit¿ renale e ossea e misurazione della DMO. L'esito primario dello studio sar¿ la variazione percentuale della DMO dal valore basale alla Settimana 96 dello studio. |
|
E.2.2 | Secondary objectives of the trial |
¿To document all serious adverse drug reactions (SADR) and all renal and bone-related adverse events (AEs), including renal and bone laboratory abnormalities ¿To determine the time to diagnosis of renal and bone AEs and document the resulting patient management and outcome(s) ¿To assess the clinical management and outcomes of renal and bone related = Grade 3 laboratory markers and clinical SAEs ¿To assess the efficacy and tolerability of Tenofovir DF in adolescents with CHB infection |
¿ Documentare tutte le reazioni avverse da farmaci serie (SADR, serious adverse drug reactions) e tutti gli eventi avversi (EA) relativi alla funzionalit¿ renale e alle ossa comprese le anomalie di laboratorio renali e ossee. ¿ Determinare il tempo alla diagnosi degli EA renali e ossei e documentare la conseguente gestione del paziente e gli esiti. ¿ Valutare la gestione clinica e gli esiti dei SAE clinici e dei marcatori di laboratorio di grado =3 relativi alla funzionalit¿ renale e ossea. ¿ Valutare l'efficacia e la tollerabilit¿ di Tenofovir DF in adolescenti con infezione CHB. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) 12 to <16 years of age 2) Documented chronic HBV infection (e.g. positive serum HBsAg >= 6 months) 3) Weight >= 35 kg 4) Able to swallow oral tablets 5) Subjects must be naïve to Tenofovir DF, but could have received interferon or any oral anti-HBV nucleoside/nucleotide therapy |
1) 12 a <16 anni di età 2) documentata infezione cronica da HBV (ad es. HBsAg sierico positivo > = 6 mesi) 3) Peso> = 35 kg 4) capacità di deglutire le compresse per via orale 5) I soggetti devono essere liberi daTenofovir DF, ma potrebbero aver ricevuto interferone o qualsiasi terapia orale anti-HBV con nucleoside/nucleotide |
|
E.4 | Principal exclusion criteria |
1)Prior Tenofovir DF therapy; subjects may have received prior interferon or oral anti HBV nucleoside/nucleotide therapy (subjects experienced on interferon must have discontinued therapy for a minimum of six months; treatment-experienced subjects receiving oral anti-HBV nucleoside/nucleotide treatment at screening should continue their current treatment regimen until Tenofovir DF is initiated (i.e., to prevent ALT flare)) 2)Sexually-active males or females of reproductive potential who are not willing to use an effective method of contraception during the study. 3)Females who are pregnant or breastfeeding, or females who wish to become pregnant during the course of the study. 4)Known hypersensitivity to Tenofovir DF, the metabolites or formulation excipients 5)Any condition (including alcohol or substance abuse) or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with treatment requirements |
1) Precedente terapia con Tenofovir DF;soggetti possono aver ricevuto prima interferone o terapia orale anti-HBV con nucleoside/nucleotide(soggetti che hanno assunto interferone devono avere interrotto la terapia per minimo 6 mesi;soggetti già trattati che ricevono terapia orale anti-HBV nucleoside/nucleotide allo screening devono continuare il loro regime di trattamento corrente fino a che Tenofovir DF verrà iniziato(ad es per prevenire sbalzo ALT)) 2) i soggetti maschi sessualmente attivi o femmine in età fertile che non sono disposti a utilizzare un metodo contraccettivo efficace durante lo studio. 3) Le donne in gravidanza o allattamento, o donne che vogliono intraprendere una gravidanza durante il corso dello studio. 4) Ipersensibilità nota a Tenofovir DF, metaboliti o formulazione di eccipienti 5) Qualsiasi condizione (incluso l'alcool o abuso di sostanze) o precedente terapia che, a giudizio dello sperimentatore, potrebbe rendere il soggetto inadatto per lo studio o non in grado di rispettare il trattamento |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The identification of bone AEs occurring in subjects taking Tenofovir DF between Baseline and Week 96 of treatment, including the identification of =4% percent reduction in BMD within subjects and between monitoring groups from Baseline. |
L'identificazione di EAs ossei che si verificano in soggetti che assumono Tenofovir DF tra il basale e la settimana 96 di trattamento, inclusa l'identificazione di una riduzione della DMO =4% tra soggetti gruppi di controllo dal basale. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Between baseline to week 96 |
tra il basale e la settimana 96 |
|
E.5.2 | Secondary end point(s) |
¿Documentation of renal or bone AEs and outcomes among subjects receiving Tenofovir DF, including rates of medication withdrawal or drug discontinuation ¿Subjects' cumulative exposure time on Tenofovir DF at the time renal or bone AEs are detected up to and including Week 96 or to study discontinuation (subjects without renal or bone AEs will contribute cumulative exposure time on Tenofovir DF from Baseline to Week 96 or to study discontinuation). The cumulative time to renal or bone AEs will be expressed as incident rates. ¿Documentation of the medical management and classification of detected renal or bone laboratory abnormalities ¿Analysis of subjects' virological and immunological status from Baseline to Week 96 under real world treatment practices |
¿ Documentazione di EAs e degli esiti renali o ossei avvenuti in soggetti trattati con Tenofovir DF, inclusi i tassi di astinenza farmaci o sospensione del farmaco ¿ tempo di esposizione cumulativa dei soggetti a tenofovir DF nel momento dell'identificazione dei EAs renali e ossei fino alla settimana 96 o per studiare la sospensione (soggetti senza EAs renali o ossei contribuiranno al tempo di esposizione cumulativa a Tenofovir DF dal basale alla settimana 96 o per studiare la sospensione). Il tempo cumulativo di EAs renali o ossei verr¿ espresso come i tassi di incidenza. ¿ Documentazione della gestione medica e classificazione delle rilevato anomalie di laboratorio renali o ossee ¿ Analisi dello stato virologico e immunologico dei soggetti dal basale alla settimana 96 sottoposti a pratiche di trattamento reali |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Between baseline to week 96 |
tra il basale e la settimana 96 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Pharmacoepidemiology |
Farmacoepidemiologia |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Monitoraggio standard versus un monitoraggio approfondito |
Standard monitoring versus enhanced monitoring |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 25 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |